Navigation Links
AlphaMed Pharmaceuticals Announces Breakthrough in the Development of Recombinant Alpha 1-Antitrypsin
Date:3/7/2008

LARGO, Fla., March 7 /PRNewswire/ -- AlphaMed Pharmaceuticals Corporation announced today that the Company has successfully expressed a humanized version of the therapeutic protein alpha 1-antitrypsin (AAT). AlphaMed scientists expressed their recombinant AAT utilizing the Company's proprietary production system in yeast. The yeast has been genetically altered to produce a molecule "virtually identical" to that which is manufactured by the human body.

"This marks a major milestone for this company and AAT research," stated Joseph McGuirl, AlphaMed's CEO, "AlphaMed is the first company to develop an AAT molecule with glycosylation that resembles the human protein that is naturally secreted from the liver. The Company has begun to develop products to treat a variety of diseases including hereditary emphysema, COPD, asthma and cystic fibrosis." Joseph McGuirl joined AlphaMed in July, 2007 and is the former Head of Licensing and Development for Hoffmann-LaRoche.

"I am glad to confirm that the work progressed well so far," stated Dr. Roland Contreras Ph.D. of the VIB, University of Ghent located in Belgium who has been supervising AlphaMed's molecular biology. "The two complex sugars of the left arm have been added with good efficiency. This is an important milestone and in my opinion a glycoform worth purifying. It is a mammalian hybrid form."

Plasma-derived AAT is currently marketed by several companies for the treatment of hereditary emphysema and generates over $200 Million in revenues, annually. The plasma-derived AAT, however, is marked by shortages and blood contamination risks.

In addition, AAT plays a vital role in the inflammatory cascade and in many instances can act as a replacement for conventional steroids. Additional disease indications treatable by AAT therapy include atopic dermatitis, psoriasis, rheumatoid arthritis and others. "The market potential for AAT therapies is in the billions," stated McGuirl, "and given AlphaMed's intellectual property position this news represents a major leg up for the company".

AlphaMed is currently seeking developmental partners to continue its research for both topical and injectible/inhalable AAT therapies. The Company has successfully completed its second round of financing and has initiated a third round to complete Phase I clinical trials and initiate Phase II clinicals.

AlphaMed Pharmaceuticals Corporation is a privately held biopharmaceutical company located in Largo, Florida. Incorporated in 1999, the Company is dedicated to the successful development of both pharmaceutical and over-the counter products for human and animal use. AlphaMed's product pipeline includes AAT for pulmonary and dermatological use as well as cromolyn sodium for a variety of topical indications. AlphaMed expects its first product to market in early 2009.


'/>"/>
SOURCE AlphaMed Pharmaceuticals Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine technology :

1. Memory Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Financial Results
2. Arriva Pharmaceuticals Moves Forward to Phase 2b Development of Lead Inhaled Protein rAAT Replacement Therapy for Hereditary Emphysema
3. NexGenix Pharmaceuticals Presents Data on a Novel Small Molecule Inhibitor of Heat Shock Protein 90 (Hsp90) at the GTCbio Cancer Drugs Research & Development Conference
4. ISTA Pharmaceuticals Announces Physician-Sponsored Clinical Study of Xibrom(TM) Combination Therapy with Lucentis(R)
5. Memory Pharmaceuticals & Roche Expand Development Program for MEM 3454 in Schizophrenia
6. Poniard Pharmaceuticals Announces Positive First-line Phase 1 Safety and Efficacy Data With Picoplatin in Metastatic Prostate Cancer Patients
7. Indevus Pharmaceuticals Provides Update on PRO 2000 Program
8. Keryx Biopharmaceuticals Completes SUN-MICRO Phase 3 Pivotal Trial
9. Lotus Pharmaceuticals, Inc. Achieves Significant Milestones in the Development of Isosorbide Mononitrate Sustained Release Tablets
10. Tigris Pharmaceuticals Initiates Phase I Study of AFP-464 in Patients with Solid Tumors
11. Peregrine Pharmaceuticals Opens Enrollment in Phase II Clinical Trial of Bavituximab in Patients with Advanced Breast Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/22/2017)... -- Kalorama Information has noted five news developments in ... industry.  This month the FDA granted a CLIA waiver to ... market has reached $18.4 billion in sales and continues ... battle and the acquisition by Abbott is still in ... chemistry analyzer and researchers evaluated fetal fibronectin screening for ...
(Date:3/22/2017)... , March 22, 2017 NetworkNewsWire Editorial ... ... given differing statements by White House officials. Federal laws are ... marijuana for medical and/or recreational use, and businesses like SinglePoint, ... Inc. (NASDAQ: CRBP), Medical Marijuana, Inc. (OTC: MJNA), Cannabis Science, ...
(Date:3/22/2017)... March 22, 2017  Based on its recent ... & Sullivan recognizes GE Healthcare with the 2016 ... Award. GE Healthcare,s strategy of innovating and expanding ... allowed it to effectively compete in a mature, ... In addition to aiding patient and clinician workflows, ...
Breaking Medicine Technology:
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... Old School ... boxing champ Ashley Theophane as a new Brand Ambassador. Theophane, who trained with Floyd ... welterweight title in 2011. He has racked up an impressive number of wins in ...
(Date:3/22/2017)... (PRWEB) , ... March 22, 2017 , ... ... solution provider, today announced that its digital marketing solutions have enabled Children’s Hospital ... investment in 24 months. , Recognizing the value of a digital marketing ...
(Date:3/22/2017)... ... March 22, 2017 , ... ... into a research collaboration to translate advances in basic neuroscience at the BMRI ... and beyond. The collaboration seeks to improve movement, vision, and cognition impaired by stroke, ...
(Date:3/22/2017)... Norwich, NY (PRWEB) , ... March 22, 2017 , ... ... to communities in the greater Nassau County region, is embarking on a combined charity ... breast cancer. , For the last 25 years, the Great Neck Breast Cancer ...
(Date:3/22/2017)... NC (PRWEB) , ... March 22, 2017 , ... Chris ... assistance to families and business professionals throughout the coastal plains region, is initiating a ... to overcome cancer. , Dillyn was first diagnosed with leukemia on a Friday evening ...
Breaking Medicine News(10 mins):